Factor V and thrombotic disease: description of a janus-faced protein.
The generation of thrombin by the prothrombinase complex constitutes an essential step in hemostasis, with thrombin being crucial for the amplification of blood coagulation, fibrin formation, and platelet activation. In the prothrombinase complex, the activated form of coagulation factor V (FVa) is an essential cofactor to the enzyme-activated factor X (FXa), FXa being virtually ineffective in the absence of its cofactor. Besides its procoagulant potential, intact factor V (FV) has an anticoagulant cofactor capacity functioning in synergy with protein S and activated protein C (APC) in APC-catalyzed inactivation of the activated form of factor VIII. The expression of anticoagulant cofactor function of FV is dependent on APC-mediated proteolysis of intact FV. Thus, FV has the potential to function in procoagulant and anticoagulant pathways, with its functional properties being modulated by proteolysis exerted by procoagulant and anticoagulant enzymes. The procoagulant enzymes factor Xa and thrombin are both able to activate circulating FV to FVa. The activity of FVa is, in turn, regulated by APC together with its cofactor protein S. In fact, the regulation of thrombin formation proceeds primarily through the upregulation and downregulation of FVa cofactor activity, and failure to control FVa activity may result in either bleeding or thrombotic complications. A prime example is APC resistance, which is the most common genetic risk factor for thrombosis. It is caused by a single point mutation in the FV gene (factor V(Leiden)) that not only renders FVa less susceptible to the proteolytic inactivation by APC but also impairs the anticoagulant properties of FV. This review gives a description of the dualistic character of FV and describes the gene-gene and gene-environment interactions that are important for the involvement of FV in the etiology of venous thromboembolism.
Nicolaes
Gerry A F
GA
Department of Laboratory Medicine, Division of Clinical Chemistry, Lund University, The Wallenberg Laboratory, University Hospital Malmö, Malmö, Sweden.
Dahlbäck
Björn
B
D020016:Activated Protein C Resistance / Q000235:genetics; D001777:Blood Coagulation / Q000502:physiology; D005165:Factor V / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D005169:Factor VIII / Q000235:genetics / Q000502:physiology; D015943:Factor Va / Q000235:genetics / Q000502:physiology; D015951:Factor Xa / Q000378:metabolism / Q000502:physiology; D006801:Humans; D010641:Phenotype; D017354:Point Mutation; D011486:Protein C / Q000235:genetics / Q000502:physiology; D017293:Protein S / Q000502:physiology; D013917:Thrombin / Q000378:metabolism; D020246:Venous Thrombosis / Q000097:blood* / Q000235:genetics; D044465:White People
D011486:Protein C; D017293:Protein S; C095381:factor V Leiden; C022475:prothrombinase complex; D015943:Factor Va; D005165:Factor V; D005169:Factor VIII; D013917:Thrombin; D015951:Factor Xa